Inactive Instrument

Hamlet Pharma AB (publ) Stock

Equities

HAMLET B

SE0015661152

Dynamic Chart
Hamlet BioPharma Announces Commercial Collaborations with Top International Advisory Firms CI
Hamlet BioPharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Hamlet Biopharma Announces New Analyses of Clinical Data from Alpha1h Treated Patients with Bladder Cancer Detect A Strong Immune Response with Known Anti-Tumor Effects CI
Hamlet Biopharma AB Announces Antimicrobial Peptide Therapy for Tuberculosis Infections CI
Hamlet Biopharma's Continued Development of Brain Tumor Therapy CI
Hamlet BioPharma Receives U.S. FDA Fast Track Designation for Alpha 1H for the Treatment of Non-Muscle Invasive Bladder Cancer CI
Hamlet BioPharma AB Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Hamlet BioPharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023 CI
Hamlet BioPharma AB Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Hamlet Pharma Announces FDA Clearance of IND Application for Alpha1H for the Treatment of Non-Muscle Invasive Bladder Cancer CI
Hamlet Pharma Announces CEO Changes CI
Hamlet Pharma Secures Long-Term Alpha1 Peptide Production in an Agreement with Polypeptide Group CI
Hamlet Pharma Secures New Alpha1H Production Batch for Continued Clinical Trials CI
Hamlet Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Hamlet BioPharma AB (NGM:HAMLET B) completed the acquisition of Selectimmune Pharma AB. CI
More news
Managers TitleAgeSince
Chief Executive Officer - 22-04-04
Members of the board TitleAgeSince
Chairman 75 99-03-28
Director/Board Member - 21-03-21
Director/Board Member 78 -
More insiders
Hamlet Pharma AB is a Sweden-based company that develops cancer therapeutics. The Company develops cancer therapeutics based on research into protein complexes that selectively induce cell-death in tumours. HAMLET, which stands for Human Alpha-lactalbumin Made LEthal to Tumours, is a protein-fatty acid complex derived from human milk. The complex induces apoptosis in tumour cells while leaving normal cells unaffected. In laboratory experiments, HAMLET is active against many different types of tumour cells, and uses several mechanisms to trigger cell death. HAMLET is also being evaluated clinically on skin papillomas and on bladder cancers. Alpha1H is a Company's drug candidate for bladder cancer in ongoing phase I/II clinical trials.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. HAMLET B Stock